Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus

Rheumatology

Volumn 51, Issue 4, 2012, Pages 663-669

  Lerang, Karoline ^a,b   Gilboe, Inge Margrethe ^a   Gran, Jan Tore ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Anti phospholipid antibody; Hydroxychloroquine; Physician's practice patterns; Prescription pattern; Systemic lupus erythematosus

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ARTHRITIS; ARTICLE; CAUCASIAN; CLINICAL FEATURE; DISCOID LUPUS ERYTHEMATOSUS; FEMALE; HEMATOLOGY; HUMAN; INFECTIOUS DISEASE MEDICINE; INFLAMMATION; INTEGRATED HEALTH CARE SYSTEM; KIDNEY DISEASE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; MEDICATION THERAPY MANAGEMENT; MOUTH ULCER; NEPHROLOGIST; NEUROLOGIC DISEASE; NORWAY; ONSET AGE; PATIENT CARE; PATIENT CODING; PATIENT IDENTIFICATION; PATIENT MONITORING; PHOTOSENSITIVITY; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE PRACTICE; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; CHILD; DRUG UTILIZATION; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; HYDROXYCHLOROQUINE; INTERPROFESSIONAL RELATIONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICINE; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATOLOGY; YOUNG ADULT;

EID: 84858646445     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker318     Document Type: Article

References (30)

1. Molina MJ, Mayor AM, Franco AE et al. Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis 2008;18:S2-10.
2. Schmajuk G, Yazdany J, Trupin L et al. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res 2010;62:386-92.
3. Gilboe IM, Husby G. Application of the 1982 revised criteria for the classification of systemic lupus erythematosus on a cohort of 346 Norwegian patients with connective tissue disease. Scand J Rheumatol 1999;28:81-7.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
5. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
6. Schjetlein R, Sletnes KE, Wisloff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb Res 1993;69:239-50.
7. Jonsson H, Nived O, Sturfelt G et al. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990;29:185-8.
8. Sanchez ML, Alarcon GS, McGwin G Jr et al. Can the weighted criteria improve our ability to capture a larger number of lupus patients into observational and interventional studies? A comparison with the American College of Rheumatology criteria. Lupus 2003;12:468-70.
9. Lofstrom B, Backlin C, Sundstrom C et al. Myeloid leukaemia in systemic lupus erythematosus-a nested case-control study based on Swedish registers. Rheumatology 2009;48:1222-6.
10. Johnson AE, Gordon C, Palmer RG et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8.
11. Wallace DJ. Antimalarials-the 'real' advance in lupus. Lupus 2001;10:385-7.
12. Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
13. Yazdany J, Panopalis P, Gillis JZ et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009;61:370-7.
14. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010;19:440-5.
15. Moroni G, Ventura D, Riva P et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36.
16. Norby GE, Strom EH, Midtvedt K et al. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study. Ann Rheum Dis 2010;69:1484-7.
17. Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008;67: 195-205.
18. Eilertsen GO, Fismen S, Hanssen TA et al. Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrol Dial Transplant 2010;26:620-7.
19. Cohen D, Berger SP, Steup-Beekman GM et al. Diagnosis and management of the antiphospholipid syndrome. Br Med J 2010;340:c2541.
20. Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosusrelated APS. J Rheumatol 2008;35:1983-8.
21. Shinjo SK, Bonfa E, Wojdyla D et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855-62.
22. Nossent J, Kiss E, Rozman B et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
23. Yazdany J, Gillis JZ, Trupin L et al. Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. Arthritis Rheum 2007;57:593-600.
24. D'Cruz D. Antimalarial therapy: a panacea for mild lupus? Lupus 2001;10:148-51.
25. Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis 1960;19:243-50.
26. Scherbel AL. Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: historic and therapeutic perspectives. Am J Med 1983;75:1-4.
27. Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008;17:271-3.
28. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
29. Mosca M, Tani C, Aringer M et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011;10: 383-8.
30. Norby GE, Lerang K, Holdaas H et al. [Lupus-nephritis-diagnosis and treatment]. Tidsskr Nor Laegeforen 2010;130:1140-4.